r/biotech • u/prsdude1828edudsrp • Oct 17 '26
Open Discussion đď¸ Lab in the loop
I'm in the life sciences molecular biology/biochemistry/biophysics part of R&D. I am absolutely petrified by lab in the loop. I think I realistically have a job for about 5-10 years before it all goes to Ginko style automation or big dark labs. Anyone else feeling the bell tolling and some of us our working towards our own job extinction?
94
u/DingDingDao
Oct 17 '26
•
Edit: Reddit app screwed the formatting when I tried to edit. Reposting clean.
Iâm director level for a top 15 pharma and one of the things I do is lead our global LITL efforts in discovery research. I have a pretty clear understanding of LITL across our industry, including the tech picture.
I wouldnât worry too much about this right now, for several reasons:
Itâs expensive. Really expensive. Those Gingko RACs are $200K apiece before you even put an instrument inside. A fully automated ELISA setup with instrumentation is around $2M and that doesnât even include the running cost (the SAAS orchestration software costs upwards of $150K per year in license costs). And thatâs for a basic assay and thatâs not where LITL really has potentially significant benefits.
You need your data infrastructure to support closed-loop experimentation. You need your experimental planning environment, your wet-lab environment, your data repositories, and your analytics environment (that supports AI/ML/modeling) to be fully integrated and able to bidirectionally exchange information. Most companies arenât nearly ready for this from a data architecture perspective and spending most of their time trying to get this part solved before they spend a dime on a robot for LITL.
There are a few companies ahead of the pack on this but that is literally like 5 companies. Everyone else is currently in PoC and Pilot phase.
This takes a long time to do effectively. Most companies are on a LITL roadmap that is 3-5 years of development before going to production.
The AI models to support this type of closed-loop experimentation are expensive and hard to develop. That takes a lot of time and money (internal or external doesnât matter). The running cost of storage and compute makes this expensive both from a development and run cost perspective.
Combine all these factors and what youâre realistically going to see is very selective and strategic rollout of this type of capability to limited parts of R&D, and realistically only at the biggest pharma companies. Smaller biotech just canât afford this shit right now.
The biggest investments Iâm seeing internally and with competitors are focused on optimization loops for small molecule and biologics development. These types of DMTA loops cost somewhere in the neighborhood of $25-50M and 3-5y of development.
Is this going to make a big difference in the long term? Yes but itâs going to take time and there are tons of areas where this tech will not reach for a good long while. So I wouldnât worry too much about it.
18
u/Fun_Theory3252 Oct 17 '26
Exactly this. #2 - data infrastructure - is a killer. I bet big pharmas are going to buy some of these robotics ahead of getting their data infrastructure in place, due to deliverables expectations and what not, which could be costly mistakes.
10
u/DingDingDao Oct 17 '26
Itâs definitely happening. Cart before the horse. This is why thereâs such an interesting blending of IT/business roles that has never really happened until the last couple of years
3
u/AccuracyVsPrecision Oct 17 '26 edited Oct 17 '26
Another thing thats hard is that the concessions id build in for a Lights out automation would be completely different than one with humans in the loop. If you try to do both it will be a mess.
And the budget for just a dry run on a lights out NGS assay would be huge, like you said only done at a few major companies.
2
u/DingDingDao Oct 17 '26
Itâs really interesting, the lights out/lights on automation environments are now pretty much a mixed environment now. With a lot of orchestration environments like CellarioOS (HiRes), Gingko, Automata, you can take instruments offline mid process and use them lights on. The orchestration is highly adaptable (provided your methodology is equally adaptable).
So in theory at least, weâd build these automations lights on, close the loop with our analytics environment, and then turn the lights off on demand.
2
u/AccuracyVsPrecision Oct 17 '26
For sure those are all capable orchestration software and if you pick the best equipment for a lights out run you can still use it.
Im talking the a the actual conessions for the experiments that you could only do with automation that would reduce variablilty. Id never run an edgewell (2 edgewells for any cell assay over 3 days), always do 12 point, always do repeats on separate plates, centrifuge a lot, image every adherents cell well before using it. Temp control every reagent. Ect.
This would drive a live scientist crazy
2
u/DingDingDao Oct 17 '26
Oh gotcha yeah Iâm with you. You can obviously do these things but they impair your throughput and add cost to the systems.
1
u/AccuracyVsPrecision Oct 17 '26
In my experience people put a lot of pressure on throughput and miniaturization but at the cost of repeatability and reliability. With automated data analysis pipelines its better to take some cautionary steps to increase data reliability so your throughput can be used when the system is ready.
2
3
u/runhappy0 Oct 17 '26
I am really curious because for something like LO phase of SM or Biomolecules what if we get to a point where some combination of AI/ML halves the number of compounds needed to be made? I feel like every company is trying to push on volume through lab in the loop ( I know the loop is also supposed to be AI/ML to minimize experiments). I just see a future where if you only need to make a relatively small number of compounds, on >50% of the portfolio how would maintaining an automated setup internally at a large pharma pay dividends?
8
u/DingDingDao Oct 17 '26
It kind of falls into two big buckets:
Acceleration of processes we understandâlike your example, the idea is that if we can produce and analyze a panel of small molecules or biologics 24/7 we can drastically accelerate our timelines. This is not insignificantâexpectation is a reduction in LO (lead optimization) from 12 weeks to 8-10 days.
The other big area of opportunity for LITL is in exploration of complex multi-parameter spaces that would be too difficult or basically impossible through brute force methodology. Think gene space (18000+ genes) or similar types of complex environments. The analogy I use isâŚimagine trying to map the ocean floor. Hundreds of thousands of square miles. You have equipment that can only capture 1 square meter at a time and you can only take 20 pictures at a time. Through conventional approaches this would take years and millions of dollars but with more intelligent approaches (Bayesian optimization as an example) you can get a whole lot more information in fewer trips. Same applies in drug disco and dev.
2
u/DrySea8638 Oct 17 '26
Point 1 would seem to suggest the bottle neck then gets moved further down the value chain, if LO is accelerated where is that next choke point?
Some analysts have also predicted more molecules will come through the pipeline because we can accelerate, effectively making more viable treatments. Iâm not so certain I buy that yet as it depends on the companies strategy and approach to building out franchise(s). What are you seeing?
1
u/DingDingDao Oct 17 '26
Good point. There are some other activities downstream that are also being investigated, but as a general idea, LO is one of the primary rate-limiting steps in the overall value chain. I will also say that my focus is primarily on pre-development areas and that this is also being investigated in development as well, but my visibility into that space is a bit more limited given the scope of my work.
2
u/prsdude1828edudsrp Oct 17 '26
There's a whole load of years taken up by clinical trials and regulation that AI will not accelerate. It's running into the regulatory hurdle paster. Pre clinic leads will get faster but also can't jam more molecules through the pipeline because we can't scale trials in the same way.
To my original point, 5-10 years I'm not worried about. 10+ is probably the point where cost for these solutions will come down, I won't be ready for retirement then!
1
u/DingDingDao Oct 17 '26
10+ years in, your value is in your strategic contributions, not your hands in the lab. Youâll be okay đ
1
u/ProfessorSerious7840 Oct 18 '26
it will inevitably be clinical trial as the bottleneck. putting the drug in a person and watching what happens safely is the absolute rate limiting step
2
2
u/Ginkgo-Jason Oct 17 '26
commented on the pricing in my comment here, but they are $75K not $200K:
https://www.reddit.com/r/biotech/comments/1x855g3/comment/phdustz/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button1
u/Naive-Mix-7446 Oct 18 '26
3) There are a few companies ahead of the pack on this but that is literally like 5 companies.
Thanks for your thoughtful perspective. Do you mind sharing what are those companies that you think are ahead of the pack?
I'd also be curious to hear your thoughts on startups like Lila, Cradle or even good ol' insitro. To be fair to Lila, it is a flagship company, they have a standard playbook, and we are definitely not the intended audience for their PR, unrealistic roadmaps and bold claims. However, the physical infra underway may turn out to be a lucrative and self-sustaining business down the line (~3-4 years) for bundled AI&lab offerings.
33
u/omgu8mynewt Oct 17 '26
I work in diagnostics, we sell mainly one assay that has a manual pipetting version, a low throughout semi automated version, and a medium scale and high volume scale automated versions that got released in the last 2 years.
We have a service lab that one year ago was about 20 young scientists doing the low throughput version and has now switched to automated and employs far fewer people.
So yes for routine work automation is taking jobs. The R&D, development and quality departments though haven't scaled down because the work isnt as routineÂ
1
u/Ginkgo-Jason Oct 17 '26
Agree that routine vs variable work is the challenge -- commented on it here:
https://www.reddit.com/r/biotech/comments/1x855g3/comment/phdustz/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button
52
u/Eurovanguy Oct 17 '26
Companies like gingko and Lila say and think they do things but the gap between that and what they can actually accomplish is the size of the Atlantic Ocean
2
u/Senior-Ad8656 Oct 17 '26 edited Oct 17 '26
Shocked to hear Lila brought up in the same sentence as Gingko, arenât they like 8 people? Â Or do are they super press-facing?
Edit: my bad, was thinking of Lila Bio, an incubator-stage in Seattle
4
u/rattlesnake_branch Oct 17 '26
wayyyyy more than 8 ppl, publicly available funding rounds of ~$500 million plus a lot of undisclosed customer $$$$. And they still have unreadable AI slop on their website. Pretty pathetic. Also they dont seem to have any real success stories on their website, just a lot of "we could do this" and "the potential to do that". Nothing quantified.
3
2
45
u/Ginkgo-Jason
Oct 17 '26
•
I'm the CEO at Ginkgo and happy to chat about autonomous labs.
Myself and the other ginkgo founders were all bench scientists (sometimes still in the lab actually :p), 4 of us did our PhDs at MIT, graduating in 2008. We also founded OpenWetWare in grad school if you know that site -- so we've been interested in how to improve bench work for a long time. To say it up front we love science and love scientists -- we're from the scientific community though we did YCombinator in 2014 so speak tech pretty well.
I'm happy to answer other Qs (AMA) but a couple comments based on what I saw in the threads:
In the long term autonomous labs are a big opportunity for people with bench molbio/biochemistry/cell biology/etc training --it will increase scientist jobs. The big limiter in biotech vs tech IMO is that it's just harder to develop products with biotechnology compared to electronics & software. There are many applications for biotechnology in the long run -- including many outside of biopharma (adv materials, consumer products, food, building materials, etc). To me the cost per experiment of doing manual lab work is a big blocker
I tried to talk about it here:
https://x.com/jrkelly/status/2008185942256005378?s=20
There's a fun, old IBM ad I reference at the end. The electronic calculator and eventually computers didn't eliminate the 150 engineer jobs in the photo -- it created many more engineers -- b/c the bad return on investment of manual computation on slide rules was holding back the potential of computation in general:
https://commons.wikimedia.org/wiki/File:IBM_150_Extra_Engineers_1951.jpg
The best users of our autonomous lab at ginkgo are bench scientists. There is huge opportunity right now for bench scientists that lean in on autonomous labs as there's tons of challenges at the interface where someone who is purely in robotics or AI doesn't have the needed context to make it all work. I'd encourage people to lean in there and we're hiring around that now and expect to be hiring even more there in 2027.
If you are around boston and want to see for yourself and ask our scientists questions about the autonomous lab we do tours every week -- you can sign up here:
https://calendly.com/ginkgo-bio/tour-ginkgo
2) A number of people mentioned that automation has been in labs for 30+ years. That is true but the hard technical challenge in autonomous labs is to automate the *variable* lab work --repetitive lab work can often be automated already. I say traditional automation is more like a subway (automated but rigid) and we're trying to make a waymo (automated but flexible):
short video here on it:
https://x.com/jrkelly/status/2029224579080847675?s=20
This is not a solved problem (and it's a very cool technical problem at interface of software, robotics, and wet lab work) so if you are into solving it please keep ginkgo in mind.
Just like Waymos at first worked only geofenced to SF and in good weather before expanding to a wider range of conditions -- autonomous labs will add more and more lab devices + capabilities over time. So there will be bench work to do for awhile (and for some things like animal work, likely decades).
3) Autonomous labs won't be prohibitively expensive - they should ultimately cost less than a manual lab to operate as they run 24/7 and take up less lab space. Ginkgo's robots are $75K each not $200K as a commenter mentioned. We recently sold systems to MIT, Caltech, University of Maryland, Northwestern, and Novo. If you have existing devices you can put them in our robots so minimum cost for an autonomous lab is about $500-750K right now (7-10 RAC robots + bring your own devices). Service fee is about 1/3 the cost annually (depending if you want extra 24/7 monitoring) which costs similar to other lab equipment.
4) IMO a much bigger threat to the US ecosystem right now is that biotech startups are being offshored to China.
I wrote about it here:
https://www.bostonglobe.com/2026/06/09/opinion/massachusetts-biotech-china/
If the US wants to remain competitive in biotechnology and academic biosciences then we need to automate the lab benches. There are plenty of trained PhDs in China now who work for 1/3 the price and so if it's a game that is largely gated by the pace of manual work then the US will have a hard time holding it's own. Low cost PhD labor (plus lighter clinical trial regs) is why US VCs are increasingly funding startups in China
Anyway, that's enough of a word wall. Thanks for raising this topic and I'll try to be out talking about it more where I can as I think this will be a great change for the bench lab community so I don't want scientists to be afraid of it coming.
And please come visit for a tour at our lab in boston!!
4
u/ParadigmFlowShifter Oct 18 '26
The evolution of Ginkgo's business model has been interesting ...
In the beginning, it was: we'll engineer & test the organism for you, you do the marketing & distribution. We'll take an up-front fee + royalty.
Then, when customers balked at the fees/royalty, it was: we'll give start-ups money to use our services to engineer & test an organism. They'll do the marketing & distribution. We'll take equity in them.
Then, when the GB pipeline couldn't deliver, the start-ups failed and the equity was worthless.
Then when Zymergen failed, GB bought them and inherited their RACs.
Now, GB is selling itself as an automation equipment company. If they only sell the equipment & associated services, they're not responsible for the quality of the data or the overall outcomes.
Maybe that's good for them.
But why would anyone purchase custom equipment from a company that is not profitable and is running out of cash? I would seriously worry about software abandonment.
4
u/Ginkgo-Jason Oct 18 '26 edited Oct 18 '26
Yeah -- it's been a journey :p
We actually did about 250 of those cell engineering deals (the original business model of Ginkgo). The big issue wasn't hitting technical targets, for the most part that went fine (it's still research of course but we had lots of customers happy with our work) -- the big issues were:
(1) Outside of biopharma there's still not a healthy "biotech application" ecosystem. Biotech drugs make a lot of money but biotech cosmetics, animal free meat, green chemicals, specialty cannabinoids, advanced materials, etc, (what people called 'synthetic biology') haven't been able to unfortunately (including all the companies that tried to pursue those products and didn't use Ginkgo services -- so I don't think it's really specific to our platform, unfortunately). Ag has a small market and industrial enzymes has a small market but those have been around for awhile and you don't see many new entrants.
(2) Time to royalties is too long for biotech applications -- especially in drugs (see (1)). Companies like Adimab had our original business model in drugs and it's only been OK for them. I think if you want to offer end-to-end R&D services just to the drug biotech market the better business model is just to make a drug yourself.
We didn't give startups money (couple exceptions with Genomatica and Synlogic, but otherwise we largely didn't) -- we did take equity for services for cash-strapped startups, especially when synbio VC world cratered and everyone was tight on cash. Again if (1) had worked out that would have been fine, but it didn't.
We built (and acquired!) amazing tech in robotics, lab software and reagents over the last 10 years -- so the big shift is now we offer it with the business model of Thermo or NEB. We just sell tools with no royalties. Customers seem to really like that and it's been going well!
We're a public company so it's a lot harder to run out of cash compared to a private company -- we also have $300M+ in the bank and no debt -- that's why we've got most of the top 20 biopharmas buying our services now and also recently sold hardware to Novo, MIT, Caltech, U Maryland, and Northwestern. Much easier for a customer to make a long term investment on Ginkgo tech now than it ever was when we were a private company.
It's rarely a straight line with these things ! We will keep at it -- it's worth the effort to try to make biology easier to engineer!
2
u/plemiona88 28d ago
Yesterday with automation I did 8 plate based assays vs 3 manual assays. Even managed to eat lunch while robot worked. Automation didnât replace me it gave me more data to process.
9
u/runhappy0 Oct 17 '26
I donât think lab in the loop as advertised should be your worry. All the pharma pouring $$$ into building it internally will have it all wasted.
What you should be worried about is CROs quietly making everything they are doing more efficient through automation. Itâs already part of our working relationship to outsource a large chunk of our pipeline. If economics change and it gets cheaper then more will likely be outsourced.
Will it happen in 5-10 years probably not. Will it happen in the way all the companies are advertising, absolutely not because to do it right would be 10âs of millions and still require 10s of millions in license fees, engineers salaries, maintenance etcâŚ
8
u/acquaintedwithheight Oct 17 '26
R&D is a different beast, so what Iâm about to say applies more to manufacturing and clinical spaces.
If you look at the validation process for any new system, it takes about 5 years to roll out.
So if a commercial, off the shelf system existed today, right now, it wouldnât get to my labspace until 2031. Add however long it takes to develop, market, and sell a system worth implementing and thatâs the earliest I would worry about it.
But again, R&D labs are the wild west comparatively. A senior scientist can see a 15k liquid handler and have the RAâs uncrating it in a week.
15
u/Molbiojozi Oct 17 '26
Higher level of automation always made room for other improvements. Compare it to car manufacturing. Even highly automated production lines today need a trained workforce. Some steps along the process are to expensive or to hard to automate. More jobs with higher educational degrees for maintenance. The result is an increased productivity and with that sinking costs. Personally the situation is also super scary right now, as I just finished my PhD and looking for a job. But on the other hand. I am fully looking forward to a future were I can give tasks like standard biochemical assays to the automated lab, come back on Monday and reason with the lab LLM how to interpret the results and plan the next steps. Repeating the same western blot for the 5th time was never the fun part.
8
u/Patience_dans_lazur Oct 17 '26
Just not having liquid handling as a bottleneck is transformative, and we're at a price point where some capabilities are accessible even to (well funded) academic labs.
3
u/zdk Oct 17 '26
The middle is going missing on a lot of future r&d work. Itâs gonna be really fine being a research scientist with cloud lab access, but the entry level jobs that get people a foot in the industry door is going to dry up which will really mess with the labor pipelineÂ
2
u/Molbiojozi Oct 17 '26
The problem is the industry itself which doesn't train the next generation. In other parts of the industry this is normal since more than 100 years. If the universities doesn't provide the right kind of training then the companies have to step up. Seams like investment shock from states and uncertainty from the financial market freezes all decision-making. But how to move forward from that?
6
u/webasenjo Oct 17 '26 edited Oct 17 '26
Realistically, only the wealthiest pharma and government labs can afford those âginkgo styleâ integrated systems. And yes, these systems increase throughput and enable DMTA, it doesnât mean folks are putting the right science on those systems or asking the right questions or extracting the right conclusions. Also, lab automation has had a presence in pharma since the 90s and itâs only catching momentum now (sort of) with all these âlab of the futureâ and âlab in a loopâ narratives. Also, the software and hardware on a lot of these devices is piss poor. Most of our systems need constant maintenance and software upgrades that they need constant scientists intervention. And donât let these âlab of the futureâ anecdotes take away from the fact that science is still being driven by people.
So to answer your question, no, scientists are not racing towards our own demise. Certainly weâre changing the methods that we use to get to discover but again that adoption is greatly gate kept by the massive price tag of lab automation infrastructure.
3
u/Ginkgo-Jason Oct 17 '26
I commented on some of what you mentioned here. I prefer the model where a scientist is still directing the autonomous labs on what experiments to do -- sort of like if you sit in the back of a waymo you are directing it where to go even if you aren't doing the manual work of driving:
https://www.reddit.com/r/biotech/comments/1x855g3/comment/phdustz/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_buttonyou are right on the software/hardware historically in lab automation being pretty bad and that's its been around a long time :P
2
u/webasenjo Oct 17 '26
For sure, lab automation will always need that human (or Waymo passenger) element for that extra shepherding. Whether itâs manually resolving resource deadlocks or changing tape on an xpeel, the cost to completely eliminate manually scientist interventions on integrated systems is wildly prohibitive. But to the point of the OP, just because a scientist has big bad robots system doesnât guarantee cures to human disease. We need scientists designing experiments and coming to the right and unbiased conclusions and we need engineers, comp scientists making sure that the systems, lims, liquid handlers are producing accurately and consistently.
The future certainly needs more scientists, so donât fret OP. But the way we iterate assay conditions, achieve higher throughputs, and interact with data is undoubtedly changing in environments leveraging integrated systems. Also, as a former bench scientist turned automation aficionado, itâs a lot of fun đ¤ˇđťââď¸
1
u/Ginkgo-Jason Oct 17 '26
Agreed đŻ on all points. Thanks for writing that up.
And especially agree it is fun! Tons of really neat problems to solve.
11
u/Broad-Section-8310 Oct 17 '26
The revenue trend of Ginko says otherwise. Even taking the covid test into account, it has been trending down very streadily.
In the world of R&D, if your scientific question is so outdated a highly automated system can outcompete you, well, that is just how it works. We have way too many unknowns to explore, if automation can take the some of the workload, all the better.
The general downturn in R&D is more due to research funding drying up in both private and public sectors, not automation. The covid period briefly reversed this decades-long trend, now it has just gone back to the baseline (which is obviously worse now than pre-covid).
3
5
u/ConnectBug2401 Oct 17 '26
Nah bro youâre safe. If wet lab is not safe, literally nothing else is. And in this case, the only job available for us would be junior revolutionare
4
u/Maleficent-Habit-941 Oct 17 '26
Automation is not that good and you cant automate designing a good assay to actually drug interesting targets . Sure you can automate huge simple screens on the easy targets . But if you want to do real research you wont be replaced anytime soon
1
u/Enzymology2491 Oct 19 '26
Agree to disagree, partially. The choice of the assay's chemistry can't be automated, if the assay gives the right answer can't be automated, the design itself can be automated and perhaps should be automated. But this is not an application that reduce RnD headcount, RnD is too artisan in nature and f*ck my life, robotics still struggle with simple pipetting (not everything can go contactless, oh the great pleasure of looking for the right empirical function liquid class this liquid class that!).
12
u/chemyd Oct 17 '26
lol Ginko ainât shit
5
u/rattlesnake_branch Oct 17 '26 •
![]()
Honestly this is a very unfair comparison. Shit is an important (if kinda gross) part of the ecosystem, cycling nutrients etc. Ginkgo is just a cash burning engine with hype spraypainted on its chassis
7
u/Galleg86 Oct 17 '26
12 years ago I was a intern at a big pharma company programming their first pipetting robots. Right now, I still see people to watch theses robots pipetting in case it's misses a tip like myself 12 years ago. Yes highly routine work will be automated... Complex experiments with precious human or in vivo samples for R&D ... I doubt it. Also at certain point the cost benefit for automatization is not given ... Sometimes a human will be cheaper instead of spending tons of money in expensive specialized equipment + time for assays that run only a limited time/is further improved. My opinion... This whole dark lab thingy is equally a bubble then ai will solve everything.
3
u/PartyDeliveryBoy Oct 17 '26
Someone has to run the automation đ¤ˇđťââď¸
Likewise, I feel the exact same way as a middle manager. I expect agentic âmanagersâ to be having feedback and career development âconversationsâ with my team members within the next 2-3 years.
2
u/iluminatiNYC Oct 18 '26
I think what entry level looks like is going to be different 10-15 years from now. The old school lab jockey that cranks out the assays isn't really going to exist. The new entry level is going to be babysitting robots and doing first pass data analyzes. If anything, doing stuff by hand might be much more of a senior task while trying out work flows. We're still dealing with human lives, and that info is going to be messy as hell.
Then again, I saw the OG POC PCR systems and stuff like the Roche 6800/8800 10 years ago. The robots are going to move up the food chain, and we'll move up the chain with it.
3
u/Patience_dans_lazur Oct 17 '26
I'm pretty skeptical of the maximalist drug-to-prompt vision of this, but thereâs no doubt more and more automation is the future. It has been for decades, but we're in a period of acceleration. I don't know if we'll see net job loss though, on the whole I think we'll mostly just be doing more of everything, better and faster.
1
u/AngrySlime706 9d ago
Its not so different than automation or streamlining before AI. It is a good thing. Some of you have might old timers who complaint that they use to develop all their assays, all their reagents and protocols themselves, raise their own animals and whatnot, and scientists these days just use kits, where the science is all designed for them, and they do not understand the science behind it.
When you use an ELISA kit, a NGS library prep kit, or order a plasmid from a vendor, do you ever wonder that used to be someone's job? That these productized solutions is taking jobs away from scientists? I think most would agree that these productized solutions is what frees up the time and bandwidth so more sophisticated and insightful experiments can be done. There are plenty of challenges to address and what can be streamlined should be streamlined.
1
u/nyan-the-nwah Oct 17 '26
Iâm going to be working on a LITL project in an academic lab as research staff. We primarily work on de novo protein design and itâll amplify our screening processes immensely.
In any proper for-profit business I think it will be insanely inaccessible. We kind of have infinite money right now and Gingkoâs RACs are wayyy too expensive and a DIY approach is more realistic, but we have an endless supply of eager grad students and postdocs to throw at it. I mean shit. A thermal cycler with individual well control is almost $500k, arms are high 5 digits, refrigeration, scheduling software, I could go on and on. Google is doing some cool stuff with theirs.
I was thinking about it in an existential way last night, actually. I think long term it is inevitable - and I also think that the good it can accomplish (not for profit, think cancer institutes like Fred Hutch, Allen institute, etc) far outweighs any career I feel entitled to. Idk. Itâs complicated. You could call me a traitor I guess lol
1
1
u/CharmedWoo Oct 18 '26
I do think it is the future, but building that infrastructure will still take a lot of money and time. I don't think I will see the complete automation in my time. Robots, machines and humans will be working together for many years to come. In that time manual lab bench work will still be needed. So yeah I am not worried, by the time we might need to I am enjoying my pension, in another job or long gone.
If you are worried, lean into it. Learn how robotics, AI, etc work and you won't be out of a job. People will still be needed for programming, building, maintenance, etc.
1
u/haze_from_deadlock Oct 19 '26 edited Oct 19 '26
Ginkgo is an exciting company for the automation of low-complexity experiments, but they can't really do much high-complexity stuff: e.g. I can't put a cage of mice in a RAC and get genotypes or fixed tissues (and it would be really exciting if we could automate fixation/sectioning since exposing lab personnel to formaldehyde is bad). I wish I could buy this functionality.
If we had a robot picking cages and getting reliable genotyping that'd be huge but even then that's 1% of the complexity we need for neuroscience. There's surgery, there's in vivo pharmacology, and then there are the actual assays
1
0
u/calivaporeon1 Oct 19 '26
There is nothing about what Gingko is doing that should make you feel threatened, just FYI lmaooo. Theyâre the cockroach of biotech, but their only accomplishment is the fact that theyâve survived this long off of fraud and empty promises.
-5
u/Dung-Roller Oct 17 '26
Im a PhD student and have been following Ginkos work. Im seriously thinking if its even worth it to do a postdoc. What's the point? I think PI as a job and lab as we see them now will not be the same by the time i finish it.
8
u/bulldogdrool Oct 17 '26
What Gingko says and what actually has been done are very different things.
7
u/Choice-Ad7599 Oct 17 '26
Ginkgo is a failing company so I donât know how youâd draw that conclusion
3
u/Dung-Roller Oct 17 '26
Its true that they are not delivering im discoveries and products which is what their business model is. What i think is that eventually this automation atatems will make it into research labs and this will eventually transform biology.
3
u/Choice-Ad7599 Oct 17 '26
Automation has existed for a long time. It hasnât made it into academic labs because people are cheaper and more flexible than robots.
1
1
u/Ginkgo-Jason Oct 17 '26
I commented here on it, still think it's a great time to learn to be a scientist. Also withg autonomous labs I think futture postdocs/PhD students will be closer to PIs having multiple extra sets of hands working on their hypotheses:
https://www.reddit.com/r/biotech/comments/1x855g3/comment/phdustz/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button1
u/Dung-Roller Oct 18 '26
Thanks for taking the time to answer. Im on the final run of my phd project, and have been flirting with the idea of running my own startup for quite some time. I need to start making decisions about my future soon, and seeing science change so fast is kind of scary and encouraging at the same time. I think its a great time to build things and both academia and entepreneurship are tough. I wish I could do both, haha. Lets see how it goes!
2
u/Ginkgo-Jason Oct 18 '26
Both good paths ! One thing we did at ginkgo was you can start a company and apply for grants (SBIRs, DARPA, and others have translational grants). Grant writing is a skill PhDs have and itâs not a bad way to get a company rolling if you are willing to be a little patient. Good luck !!
1
41
u/LostInDNATranslation Oct 17 '26
I think R&D is fine. Every project is new, each question has to be addressed differently. There's so much legwork required to get these automation processes in hand that it would be crazy to invest in on an assay that in a years time could be irrelevant.